Please use this identifier to cite or link to this item: http://monografias.ufrn.br/handle/123456789/10657
Title: Comparative assessment of off-label and unlicensed drug prescription in neonates: FDA vs brazilian guidelines
Authors: Florencio, Arlan Peres
Keywords: off label;off label;indicações não aprovadas;Unapproved indications;não licenciadas;Unlicensed;unidade de terapia intensiva neonatal;Neonatal intensive care unit
Issue Date: 2020
Publisher: Universidade Federal do Rio Grande do Norte
Citation: FLORENCIO, Arlan Peres. Comparative assessment of off-label and unlicensed drug prescription in neonates: FDA vs brazilian guidelines. 2020. 26f. Trabalho de Conclusão de Curso (Graduação em Farmácia) - Departamento de Farmácia, Universidade Federal do Rio Grande do Norte, Natal, 2020.
Portuguese Abstract: Introduction: Regulatory agencies are responsible for order the use of off-label (OL) and unlicensed drugs (UL) prescriptions in neonatal intensive care (NICU). However, these criteria may differ between agencies in different countries. The aim of this study were defining the incidence of off-label (OL) and unlicensed drugs (UL) prescriptions in a sample of NICU patients according to American Food and Drug Administration (FDA) and Brazilian National Health Surveillance Agency (Anvisa) and analyzing the divergences between the results. Methods: Prospective cohort study developed between August 2017 and July 2018 with neonates admitted for more than 24 hours in a teaching maternity hospital. The drugs were investigated for prescription OL and UL through DrugDexMicromedex® and the official Brazilian drug information. The kappa correlation coefficient was used to assess the agreement between the FDA and Anvisa criteria. Kappa values <0.200 were considered non-concordant. Results: During the study period, 220 neonates and 17421 prescribed items were evaluated. The proportion of neonates with at least one medication prescribed as OL does not differ between the agencies FDA and Anvisa (96.4% vs 98.6%). The FDA and Anvisa differ as to the OL classification in the ages approved for use and indications, mainly in antimicrobials for systemic use and cardiovascular drugs. When comparing drug information between the FDA and Anvisa, we highlight that the Brazilian agency is less accurate. Conclusion: The use of OL and UL drugs in neonatal intensive care is high when assessed by both regulatory agencies; however, the FDA is more accurate in describing the ages and indications approved for use.
Abstract: Introduction: Regulatory agencies are responsible for order the use of off-label (OL) and unlicensed drugs (UL) prescriptions in neonatal intensive care (NICU). However, these criteria may differ between agencies in different countries. The aim of this study were defining the incidence of off-label (OL) and unlicensed drugs (UL) prescriptions in a sample of NICU patients according to American Food and Drug Administration (FDA) and Brazilian National Health Surveillance Agency (Anvisa) and analyzing the divergences between the results. Methods: Prospective cohort study developed between August 2017 and July 2018 with neonates admitted for more than 24 hours in a teaching maternity hospital. The drugs were investigated for prescription OL and UL through DrugDexMicromedex® and the official Brazilian drug information. The kappa correlation coefficient was used to assess the agreement between the FDA and Anvisa criteria. Kappa values <0.200 were considered non-concordant. Results: During the study period, 220 neonates and 17421 prescribed items were evaluated. The proportion of neonates with at least one medication prescribed as OL does not differ between the agencies FDA and Anvisa (96.4% vs 98.6%). The FDA and Anvisa differ as to the OL classification in the ages approved for use and indications, mainly in antimicrobials for systemic use and cardiovascular drugs. When comparing drug information between the FDA and Anvisa, we highlight that the Brazilian agency is less accurate. Conclusion: The use of OL and UL drugs in neonatal intensive care is high when assessed by both regulatory agencies; however, the FDA is more accurate in describing the ages and indications approved for use.
URI: http://monografias.ufrn.br/handle/123456789/10657
Other Identifiers: 2016081845
Appears in Collections:Farmácia

Files in This Item:
File Description SizeFormat 
Comparativeassessmentofoff-label_Florencio_2020
Restricted Access Until 2023-07-08
O TCC já foi submetido para publicação
Texto Completo633.37 kBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.